Effectiveness of Digihaler System over standard-of-care in asthma management

A recent study suggests that asthma can be managed and controlled effectively using the Digihaler System (DS). The results of this study were published in The Journal of Allergy and Clinical Immunology, in Practice.

The CONNECT2 was an open-label study that included participants who were 13 years or older, having uncontrolled asthma (Asthma Control Test [ACT] score <19). They were randomized in a 4:3 ratio to either Digihaler System (DS; n=210) or standard-of-care (SoC; n=181) maintenance and reliever inhalers. DS comprised of 2 Digihaler inhalers (fluticasone propionate/salmeterol and albuterol), having an associated patient App and web-based Dashboard. The primary endpoint of the study was the proportion of patients achieving well-controlled asthma, having an ACT score ≥20 or increase from baseline of ≥3 units at week 24.

The study results showed that participants utilizing the DS had a higher chance, with a probability of 88.7%, of achieving improvement in asthma control after 24 weeks compared to individuals using SoC. The mean odds ratio between the two groups was 1.35, indicating a 35% higher odds of improved asthma control achieved with the DS. The participants' maintenance treatment adherence for DS was good; reliever use decreased by 38.2% versus baseline. Even the App and Dashboard usability was rated to be good. From the above results, it can be concluded that positive results in asthma control seen after 24 weeks may indicate the effectiveness of the DS in asthma management.